Turkiye Klinikleri Journal of Medical Sciences

.: REVIEW
Alzheimer Hastalığında Monoaminerjik Sistem Değişiklikleri: Geleneksel Bir Derleme
Alterations of Monoaminergic Systems in Alzheimer's Disease: A Traditional Review
Raviye ÖZEN KOCAa, Z. Işık SOLAK GÖRMÜŞa, Hatice SOLAKb
aNecmettin Erbakan Üniversitesi Meram Tıp Fakültesi, Fizyoloji ABD, Konya, Türkiye
bKütahya Sağlık Bilimleri Üniversitesi Tıp Fakültesi, Fizyoloji ABD, Kütahya, Türkiye
Turkiye Klinikleri J Med Sci. 2022;42(4):323-34
doi: 10.5336/medsci.2022-89011
Article Language: TR
Full Text
ÖZET
 Alzheimer hastalığı (AH); karakteristik klinik ve patolojik özelliklere sahip, yaşla ilişkili, nörodejeneratif bir hastalıktır. AH'den kaynaklanan ölüm oranı, 2020 yılında koronavirüs hastalığı 2019 pandemisi ile daha da şiddetlenmiştir. En çok bilinen nöropatolojik bulgular; ekstranöronal senil plaklar ve intranöronal nörofibriler yumaklardır. AH, monoaminerjik sistemleri de içeren birçok nöronal yapıyı etkileyen multisistemik bir hastalıktır. AH fizyopatolojisi ile nörotransmitterlerde meydana gelen fonksiyonel değişiklikler yakından ilişkilidir. Nöronal sinapsların kaybı ve nöron ölümü sonucunda asetilkolin gibi birçok nörotransmitterin azaldığı bilinmektedir. AH'de monoaminerjik sistemde temel olarak, dopaminerjik innervasyonu sağlayan substansia nigra çekirdeği, serotonerjik innervasyonu sağlayan dorsal rafe çekirdeği ve noradrenerjik innervasyonu sağlayan lokus seruleus çekirdeği, histaminerjik innervasyonu sağlayan tüberomamiller çekirdek önemli dejenerasyona maruz kalmaktadır. Bu çekirdeklerden projeksiyon alan bölgelerde ilgili nörotransmitterlerin düzeylerinde değişiklikler olmaktadır. Kombine tedavi (bilişsel geliştirici tedaviler, nöropsikiyatrik semptomları tedavi eden ilaçlar, hastalığı modifiye edici tedaviler) Alzheimer hastalarında davranışsal anormallikleri azaltmak ve kognitif fonksiyonları etkili şekilde restore etmek için önemlidir. AH için oluşturulacak tedavi stratejileri, monoaminerjik sistemin arkasındaki moleküler mekanizmayı anlamayı gerektirmektedir. Bu geleneksel derleme ile AH'de monoaminerjik sistemde özellikle dopamin, noradrenalin, serotonin ve histamin mekanizmalarında meydana gelen değişiklikleri ayrıntılı bir şekilde tartışıp, bu konuda bir bakış açısı sunmayı hedefliyoruz. Sonuç olarak monoaminerjik sistemin sinyalizasyon mekanizmasının ve monoaminerjik reseptörlerin etkilerinin daha iyi anlaşılması için insanlarda ve hayvan modellerinde daha çok çalışma yapılması gerekmektedir. Böylece, AH için yeni tedavi stratejilerinin gelişimi hızlanacaktır.

Anahtar Kelimeler: Alzheimer hastalığı; monoaminler; dopamin; noradrenalin; serotonin
ABSTRACT
 Alzheimer's disease (AD) is an age-related, neurodegenerative disease with characteristic clinical and pathological features. The death rate from AD was exacerbated by the coronavirus disease 2019 pandemic in 2020. The most common neuropathological findings are extraneuronal senile plaques and intraneuronal neurofibrillary tangles. AD is a multisystemic disease that affects many neuronal structures, including monoaminergic systems. Functional changes in neurotransmitters are closely related to the pathophysiology of AD. It is known that many neurotransmitters such as acetylcholine decrease as a result of loss of neuronal synapses and neuronal death. In the monoaminergic system, basically, the substantia nigra nucleus providing the dopaminergic innervation, the dorsal raphe nucleus providing the serotonergic innervation, the locus ceruleus nucleus providing the noradrenergic innervation, and the tuberomamillar nucleus providing the histaminergic innervation are exposed to significant degeneration in AD. There are changes in the levels of relevant neurotransmitters in the regions projected from these nuclei. Combined therapy (cognitive enhancing treatments, drugs to treat neuropsychiatric symptoms, disease-modifying therapies) important to reduce behavioral abnormalities and effectively restore cognitive functions in AD patients. Treatment strategies for AD require understanding the molecular mechanism behind the monoaminergic system. With this traditional review, we aim to discuss in detail the changes that occur in the monoaminergic system, especially in dopamine, noradrenaline, serotonin and histamine mechanisms in AD, and present a perspective on this issue. As a result; more studies in humans and animal models are needed to better understand the signaling mechanism of the monoaminergic system and the effects of monoaminergic receptors. Thus, the development of new treatment strategies for AD will accelerate.

Keywords: Alzheimer's disease; monoamines; dopamine; noradrenaline; serotonin
REFERENCES:
  1. 2021 Alzheimer's disease facts and figures. Alzheimers Dement. 2021;17(3):327-406. [Crossref]  [PubMed] 
  2. Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, et al. Alzheimer's disease. Lancet. 2021;397(10284):1577-90. [Crossref]  [PubMed]  [PMC] 
  3. Thies W, Bleiler L. Alzheimer's disease facts and figures. Alzheimers Dement. 2011;7(2):208-44. [PubMed] 
  4. Torromino G, Maggi A, De Leonibus E. Estrogen-dependent hippocampal wiring as a risk factor for age-related dementia in women. Prog Neurobiol. 2021;197:101895. [Crossref]  [PubMed] 
  5. Srivastava S, Ahmad R, Khare SK. Alzheimer's disease and its treatment by different approaches: a review. Eur J Med Chem. 2021;216:113320. [Crossref]  [PubMed] 
  6. Gültekin M. Alzheimer hastalığı tanısında güncel radyolojik yöntemler. Yener GG, Yılmaz Küsbeci Ö, editörler. Alzheimer Hastalığı. 1. Baskı. Ankara: Türkiye Klinikleri; 2021. p.61-3.
  7. Chu LW. Alzheimer's disease: early diagnosis and treatment. Hong Kong Med J. 2012;18(3):228-37. [PubMed] 
  8. Ghoweri AO, Gagolewicz P, Frazier HN, Gant JC, Andrew RD, Bennett BM, et al. Neuronal calcium ımaging, excitability, and plasticity changes in the Aldh2-/- mouse model of sporadic Alzheimer's disease. J Alzheimers Dis. 2020;77(4):1623-37. [Crossref]  [PubMed]  [PMC] 
  9. Wenk GL. Neuropathologic changes in Alzheimer's disease. J Clin Psychiatry. 2003;64 Suppl 9:7-10. [PubMed] 
  10. Trillo L, Das D, Hsieh W, Medina B, Moghadam S, Lin B, et al. Ascending monoaminergic systems alterations in Alzheimer's disease. translating basic science into clinical care. Neurosci Biobehav Rev. 2013;37(8):1363-79. [Crossref]  [PubMed] 
  11. Postupna NO, Keene CD, Latimer C, Sherfield EE, Van Gelder RD, Ojemann JG, et al. Flow cytometry analysis of synaptosomes from post-mortem human brain reveals changes specific to Lewy body and Alzheimer's disease. Lab Invest. 2014;94(10):1161-72. [Crossref]  [PubMed]  [PMC] 
  12. Szot P. Common factors among Alzheimer's disease, Parkinson's disease, and epilepsy: possible role of the noradrenergic nervous system. Epilepsia. 2012;53 Suppl 1:61-6. [Crossref]  [PubMed] 
  13. Husna Ibrahim N, Yahaya MF, Mohamed W, Teoh SL, Hui CK, Kumar J. Pharmacotherapy of Alzheimer's disease: seeking clarity in a time of uncertainty. Front Pharmacol. 2020;11:261. [Crossref]  [PubMed]  [PMC] 
  14. Martorana A, Koch G. "Is dopamine involved in Alzheimer's disease?". Front Aging Neurosci. 2014;6:252. [Crossref]  [PubMed]  [PMC] 
  15. Gallo A, Pillet LE, Verpillot R. New frontiers in Alzheimer's disease diagnostic: monoamines and their derivatives in biological fluids. Exp Gerontol. 2021;152:111452. [Crossref]  [PubMed] 
  16. Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D, et al. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci U S A. 2010;107(13):6058-63. [Crossref]  [PubMed]  [PMC] 
  17. Hirao K, Pontone GM, Smith GS. Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease. Neurosci Biobehav Rev. 2015;49:157-70. [Crossref]  [PubMed]  [PMC] 
  18. Hendricksen M, Thomas AJ, Ferrier IN, Ince P, O'Brien JT. Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer's disease with and without depression. Am J Psychiatry. 2004;161(6):1096-102. [Crossref]  [PubMed] 
  19. Zubenko GS. Neurobiology of major depression in Alzheimer's disease. Int Psychogeriatr. 2000;12:217-30. [Crossref] 
  20. Parvizi J, Van Hoesen GW, Damasio A. The selective vulnerability of brainstem nuclei to Alzheimer's disease. Ann Neurol. 2001;49(1):53-66. [Crossref]  [PubMed] 
  21. Borroni B, Agosti C, Archetti S, Costanzi C, Bonomi S, Ghianda D, et al. Catechol-O-methyltransferase gene polymorphism is associated with risk of psychosis in Alzheimer disease. Neurosci Lett. 2004;370(2-3):127-9. [Crossref]  [PubMed] 
  22. Xu Y, Yan J, Zhou P, Li J, Gao H, Xia Y, et al. Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease. Prog Neurobiol. 2012;97(1):1-13. [Crossref]  [PubMed]  [PMC] 
  23. Storga D, Vrecko K, Birkmayer JG, Reibnegger G. Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Neurosci Lett. 1996;203(1):29-32. [Crossref]  [PubMed] 
  24. Nobili A, Latagliata EC, Viscomi MT, Cavallucci V, Cutuli D, Giacovazzo G, et al. Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease. Nat Commun. 2017;8:14727. [Crossref]  [PubMed]  [PMC] 
  25. Ceyzériat K, Gloria Y, Tsartsalis S, Fossey C, Cailly T, Fabis F, et al. Alterations in dopamine system and in its connectivity with serotonin in a rat model of Alzheimer's disease. Brain Commun. 2021;3(2):fcab029. [Crossref]  [PubMed]  [PMC] 
  26. Kemppainen N, Ruottinen H, Nâgren K, Rinne JO. PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology. 2000;55(2):205-9. [Crossref]  [PubMed] 
  27. Kemppainen N, Laine M, Laakso MP, Kaasinen V, Någren K, Vahlberg T, et al. Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. Eur J Neurosci. 2003;18(1):149-54. [Crossref]  [PubMed] 
  28. Sweet RA, Hamilton RL, Healy MT, Wisniewski SR, Henteleff R, Pollock BG, et al. Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis. Arch Neurol. 2001;58(3):466-72. [Crossref]  [PubMed] 
  29. Holmes C, Smith H, Ganderton R, Arranz M, Collier D, Powell J, et al. Psychosis and aggression in Alzheimer's disease: the effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry. 2001;71(6):777-9. [Crossref]  [PubMed]  [PMC] 
  30. Meguro K, Yamaguchi S, Itoh M, Fujiwara T, Yamadori A. Striatal dopamine metabolism correlated with frontotemporal glucose utilization in Alzheimer's disease: a double-tracer PET study. Neurology. 1997;49(4):941-5. [Crossref]  [PubMed] 
  31. Tanaka Y, Meguro K, Yamaguchi S, Ishii H, Watanuki S, Funaki Y, et al. Decreased striatal D2 receptor densityassociated with severe behavioral abnormality in Alzheimer's disease. Ann Nucl Med. 2003;17(7):567-73. [Crossref]  [PubMed] 
  32. Filip V, Kolibás E. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. J Psychiatry Neurosci. 1999;24(3):234-43. [PubMed]  [PMC] 
  33. Freedman M, Rewilak D, Xerri T, Cohen S, Gordon AS, Shandling M, et al. L-deprenyl in Alzheimer's disease: cognitive and behavioral effects. Neurology. 1998;50(3):660-8. [Crossref]  [PubMed] 
  34. Mitchell RA, Herrmann N, Lanctôt KL. The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease. CNS Neurosci Ther. 2011;17(5):411-27. [Crossref]  [PubMed]  [PMC] 
  35. Herrmann N, Rothenburg LS, Black SE, Ryan M, Liu BA, Busto UE, et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol. 2008;28(3):296-301. [Crossref]  [PubMed] 
  36. Robertson IH. A noradrenergic theory of cognitive reserve: implications for Alzheimer's disease. Neurobiol Aging. 2013;34(1):298-308. [Crossref]  [PubMed] 
  37. Traver S, Salthun-Lassalle B, Marien M, Hirsch EC, Colpaert F, Michel PP. The neurotransmitter noradrenaline rescues septal cholinergic neurons in culture from degeneration caused by low-level oxidative stress. Mol Pharmacol. 2005;67(6):1882-91. [Crossref]  [PubMed] 
  38. Troadec JD, Marien M, Darios F, Hartmann A, Ruberg M, Colpaert F, et al. Noradrenaline provides long-term protection to dopaminergic neurons by reducing oxidative stress. J Neurochem. 2001;79(1):200-10. [Crossref]  [PubMed] 
  39. Mather M. Noradrenaline in the aging brain: promoting cognitive reserve or accelerating Alzheimer's disease? Semin Cell Dev Biol. 2021;116:108-24. [Crossref]  [PubMed]  [PMC] 
  40. Szot P. Elevated cerebrospinal fluid norepinephrine in the elderly can link depression and a reduced glymphatic system as risk factors for Alzheimer's disease. Journal of Aging Science. 2016;4:158. [Crossref] 
  41. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70(11):960-9. [Crossref]  [PubMed] 
  42. Kalaria RN, Andorn AC, Harik SI. Alterations in adrenergic receptors of frontal cortex and cerebral microvessels in Alzheimer's disease and aging. Prog Clin Biol Res. 1989;317:367-74. [PubMed] 
  43. Kalaria RN, Andorn AC, Tabaton M, Whitehouse PJ, Harik SI, Unnerstall JR. Adrenergic receptors in aging and Alzheimer's disease: increased beta 2-receptors in prefrontal cortex and hippocampus. J Neurochem. 1989;53(6):1772-81. [Crossref]  [PubMed] 
  44. Russo-Neustadt A, Cotman CW. Adrenergic receptors in Alzheimer's disease brain: selective increases in the cerebella of aggressive patients. J Neurosci. 1997;17(14):5573-80. [Crossref]  [PubMed]  [PMC] 
  45. Kalaria RN, Andorn AC. Adrenergic receptors in aging and Alzheimer's disease: decreased alpha 2-receptors demonstrated by [3H]p-aminoclonidine binding in prefrontal cortex. Neurobiol Aging. 1991;12(2):131-6. [Crossref]  [PubMed] 
  46. Cohen HP, Waltz AG, Jacobson RL. Catecholamine content of cerebral tissue after occlusion or manipulation of middle cerebral artery in cats. J Neurosurg. 1975;43(1):32-6. [Crossref]  [PubMed] 
  47. Bekar LK, Wei HS, Nedergaard M. The locus coeruleus-norepinephrine network optimizes coupling of cerebral blood volume with oxygen demand. J Cereb Blood Flow Metab. 2012;32(12):2135-45. [Crossref]  [PubMed]  [PMC] 
  48. Al-Nuaimi SK, Mackenzie EM, Baker GB. Monoamine oxidase inhibitors and neuroprotection: a review. Am J Ther. 2012;19(6):436-48. [Crossref]  [PubMed] 
  49. Hornung JP. The human raphe nuclei and the serotonergic system. J Chem Neuroanat. 2003;26(4):331-43. [Crossref]  [PubMed] 
  50. Meneses A, Hong E. 5-HT1A receptors modulate the consolidation of learning in normal and cognitively impaired rats. Neurobiol Learn Mem. 1999;71(2):207-18. [Crossref]  [PubMed] 
  51. Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2007;95(1-3):158-68. [Crossref]  [PubMed] 
  52. Truchot L, Costes N, Zimmer L, Laurent B, Le Bars D, Thomas-Antérion C, et al. A distinct [18F]MPPF PET profile in amnestic mild cognitive impairment compared to mild Alzheimer's disease. Neuroimage. 2008;40(3):1251-6. [Crossref]  [PubMed] 
  53. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000;20(24):9104-10. [Crossref]  [PubMed]  [PMC] 
  54. Van Meer P, Raber J. Mouse behavioural analysis in systems biology. Biochem J. 2005;389(Pt 3):593-610. [Crossref]  [PubMed]  [PMC] 
  55. Inagaki N, Toda K, Taniuchi I, Panula P, Yamatodani A, Tohyama M, et al. An analysis of histaminergic efferents of the tuberomammillary nucleus to the medial preoptic area and inferior colliculus of the rat. Exp Brain Res. 1990;80(2):374-80. [Crossref]  [PubMed] 
  56. Cacabelos R, Yamatodani A, Niigawa H, Hariguchi S, Tada K, Nishimura T, et al. Brain histamine in Alzheimer's disease. Methods Find Exp Clin Pharmacol. 1989;11(5):353-60. [PubMed] 
  57. Naddafi F, Mirshafiey A. The neglected role of histamine in Alzheimer's disea se. Am J Alzheimers Dis Other Demen. 2013;28(4):327-36. [Crossref]  [PubMed] 
  58. Nomura H. [Histamine signaling restores retrieval of forgotten memories]. Nihon Yakurigaku Zasshi. 2021;156(5):292-6. [Crossref]  [PubMed] 
  59. Zlomuzica A, Dere D, Binder S, De Souza Silva MA, Huston JP, et al. Neuronal histamine and cognitive symptoms in Alzheimer's disease. Neuropharmacology. 2016;106:135-45. [Crossref]  [PubMed] 
  60. Perez SE, Nadeem M, Sadleir KR, Matras J, Kelley CM, Counts SE, et al. Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice. Int J Physiol Pathophysiol Pharmacol. 2012;4(3):115-27. [PubMed]  [PMC] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com